Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capivasertib + sunitinib
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Capivasertib + sunitinib is an investigational combination of two small molecule kinase inhibitors, each with distinct but potentially complementary mechanisms of action in oncology. Capivasertib is a selective inhibitor of all three isoforms of the serine/threonine kinase AKT (AKT1, AKT2, and AKT3), a key node in the PI3K/AKT signaling pathway that regulates cell proliferation and survival. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that blocks several receptors involved in tumor angiogenesis and growth, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, FLT3, CSF1R, and RET. Both drugs are approved individually for various cancers but there is no evidence from the provided sources or current literature that this specific combination has been approved or widely studied together as a fixed regimen.
- Brand names
- Truqap (capivasertib)Sutent (sunitinib)
- Other names
- capivasertib + sunitinib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)CSF1R (Macrophage colony-stimulating factor receptor)AKT2 (Rac-beta serine/threonine-protein kinase)CDK2 (Cyclin-dependent kinase 2)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)ITK (Interleukin 2-inducible T-cell kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on capivasertib + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capivasertib + sunitinib.